Signet Healthcare Partners

Juno Pharmaceuticals is a pharmaceutical company that specializes in niche injectable generic drugs.

Ascendia Pharmaceuticals

GI Supply was founded nearly 30 years ago by Dr. Frank Jackson, a gastroenterologist and entrepreneur, to help solve many of the clinical challenges he faced in daily practice. The products he built in partnership with other GI physicians and nurses, help improve physician efficiency and patient satisfaction. Today, GI Supply products are used around the world daily by gastroenterologists and colorectal surgeons in more than 40 countries.

Smart Medical Systems Ltd. develops, manufactures, and commercializes medical devices specializing in the field of gastroenterology and gastrointestinal (GI) endoscopy. The company offers NaviAid Platform designed to overcome the challenges in GI endoscopy; G-EYE endoscope that enables Controlled Withdrawal of the endoscope during colonoscopy, improving visibility of the colon and making therapy and intervention easier and faster; NaviAid AB (Advancing Balloon) device that provides ileoscopy/upper enteroscopy while using standard endoscopes; NaviAid ABC (Advancing Balloon for Colonoscopy) device for colonoscopy; NaviAid inflation systems that facilitate the operation of various balloon devices within the gastrointestinal tract; and Controlled Withdrawal technique, a feature of the G-EYE endoscope and the NaviAid family that enables a thorough investigation of the bowel, improving visibility, detection, and stability of the endoscope. It serves customers through distributors in the United States and Europe. The company is based in Ra’anana, Israel with a subsidiary operation in the United States.

Leading Pharma, LLC is a privately owned company based in Fairfield, New Jersey, specializing in the manufacture, marketing, and distribution of generic pharmaceutical products. Established in 2014, the company develops, purchases, and licenses a variety of products, particularly oral solid dosage forms, across multiple therapeutic areas. Leading Pharma supplies its offerings to a diverse clientele, including wholesalers, distributors, drugstore chains, mass merchandisers, government agencies, and managed care accounts throughout the United States. The company's commitment to quality is reflected in its focus on providing safe and effective pharmaceutical products while adhering to stringent regulatory standards. Through efficient manufacturing processes and comprehensive customer service, Leading Pharma aims to enhance access to essential healthcare products for the communities it serves.

TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, that specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. Founded in 2012, the company offers a range of products under the OviTex brand, including OviTex Reinforced Tissue Matrix for hernia repair and abdominal wall reconstruction, as well as OviTex PRS Reinforced Tissue Matrix for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically designed for laparoscopic and robotic surgical procedures, which utilize a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber. The company's marketing efforts are primarily conducted through a direct sales force operating mainly in the United States.

Pharmaceutics International, Inc. is a contract development and manufacturing organization that specializes in dosage form development and cGMP manufacturing services for the biotech and specialty pharmaceutical sectors. Founded in 1994 and headquartered in Hunt Valley, Maryland, the company offers a diverse range of dosage forms, including conventional and controlled-release tablets and capsules, soft gels, liquid formulations, inhalation products, sterile injectables, and more. In addition to manufacturing, Pharmaceutics International provides services such as pre-formulation, clinical trial materials production, commercial manufacturing, and clinical packaging and labeling. The company is committed to delivering high-quality services and has built a balanced client base that includes major multinational and emerging pharmaceutical companies worldwide. Its focus on scientific expertise, customer service, and quality has positioned Pharmaceutics International as a key player in pharmaceutical product development outsourcing.

leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs. leon-nanodrugs offers access to the next generation of nano-formulated drugs with meaningful differentiation and added patient benefits. They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles.

BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships. It is licensed to do business in the United States and is accomplished in the areas of product development, regulatory affairs, quality management, sales and distribution, and supply chain management. Today, Bionpharma is one of the largest suppliers of soft gel capsules in the US market with a strong presence in both the prescription and over-the-counter markets. Launched in 2014, BionPharma was founded by a team of executives and professionals with years of cumulative experience in the generics industry. It is based in Princeton, New Jersey, and with offices in Raleigh, North Carolina.

KEW, Inc. is a genomic testing company focused on personalized cancer treatment. Based in Cambridge, Massachusetts, it offers a range of services that assist oncologists in making informed treatment decisions based on the genetic characteristics of individual tumors. KEW utilizes its proprietary CANCERPLEX testing service, which includes various panel options such as CANCERPLEX FP for full genomic analysis, CANCERPLEX TS for specific tumor types, and CANCERPLEX TX for FDA-approved targeted therapies. By providing these genomic insights, KEW aims to enhance the precision of oncology care, enabling healthcare providers to deliver tailored therapies that align with each patient's unique genetic profile. The company was founded in 2009 and has evolved to support community oncology practices in optimizing patient care through advanced genomic information.

Sancilio and Company, founded in 2004 and headquartered in Riviera Beach, Florida, specializes in the development, manufacturing, and distribution of biopharmaceutical products, including over-the-counter items and dietary supplements. The company offers a range of products targeting cardiovascular health, dental health, and women's health. Notable offerings include OCEAN BLUE PROFESSIONAL OMEGA-3 for cardiovascular support and LUDENT SODIUM FLUORIDE CHEWABLE TABLETS for children's dental health. Sancilio also provides a variety of women's health products, such as Mylk, a multivitamin softgel, and Caltranate, a calcium supplement. In addition to its product lines, the company offers pharmaceutical services, encompassing analytical chemistry, formulation development, and contract manufacturing, among others. Despite its comprehensive portfolio, Sancilio and Company filed for Chapter 11 bankruptcy and ceased operations as of May 31, 2019.

Fluxion Biosciences, Inc. develops analytical instruments for functional cellular analysis aimed at life sciences, drug discovery, and diagnostic applications. Founded in 2005 and based in Alameda, California, the company specializes in a proprietary microfluidic platform that allows for precise cellular manipulation and rapid compound addition. Its primary offerings include the IsoFlux Liquid Biopsy System, designed for enriching rare cell populations such as circulating tumor cells, as well as various cell enrichment and downstream analysis kits. Additionally, Fluxion provides BioFlux systems for live cell analysis under shear flow and IonFlux systems for automated patch clamping. The company serves a diverse clientele, including biotechnology and pharmaceutical firms, academic institutions, and government research organizations, and offers its products through a network of distributors both domestically and internationally.

Arbor Pharmaceuticals is a specialty pharmaceutical company based in Raleigh, North Carolina, established in 2006. The company focuses on pediatric medicine, engaging in the licensing, development, and commercialization of late-stage products aimed at treating common pediatric conditions. Its product portfolio includes treatments for acute otitis externa and acute otitis media, such as ZINOTIC and NEOTIC, as well as XYLAREX for dietary management of recurrent acute otitis media. Additionally, Arbor Pharmaceuticals offers the Pediaderm HC Complete Kit for children with atopic dermatitis. The company utilizes specialized sales forces to market its products throughout the United States, while also having interests in cardiology, neurology, endocrinology, and orphan products, providing safe and effective medications that aim to improve patient outcomes.

Pfenex Inc. is a biotechnology company based in San Diego, California, specializing in the development of protein therapies to address unmet medical needs. The company is known for its lead product candidate, PF708, which is a therapeutic equivalent to Forteo for treating osteoporosis. Other notable candidates include PF743, a recombinant crisantaspase, and PF745, an extended half-life version of the same protein. Pfenex is also advancing PF810, a next-generation therapeutic in preclinical development, along with additional products such as sparX-1 and sparX-2. The company's innovative Pfēnex Expression Technology, which employs the microorganism Pseudomonas fluorescens, facilitates the rapid and efficient production of therapeutic proteins, vaccines, and biosimilars. Pfenex also holds license and supply agreements for CRM197, a non-toxic variant of diphtheria toxin. As of late September 2020, Pfenex operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

SpePharm is a European specialty pharmaceutical company dedicated to acquiring, registering and marketing high medical value medicines throughout Europe, essentially for the hospital market. The SpePharm management team has a wealth of global experience within the pharmaceutical industry. In particular, the team has a well-established and in-depth knowledge of the European regulatory system, the hospital market, and niche and orphan products, with novel approaches and proven successes.

PEAK Surgical is a medical device company based in Palo Alto, California, focused on developing surgical tools that combine the precision of a scalpel with the bleeding control typical of traditional electrosurgery. The company's flagship product, the PEAK Surgery System, includes a range of disposable cutting devices designed to minimize collateral damage during surgical procedures. This innovative system is approved for use in various surgical fields, including general, plastic and reconstructive, ENT, gynecologic, orthopedic, arthroscopic, spinal, and neurological surgeries in the United States, as well as general surgery in the European Union. PEAK Surgical aims to fill a critical gap in the surgical market by providing enhanced tools for physicians.

DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaders such as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors.

Alpex Pharma SA is a pharmaceutical company based in Mezzovico-Vira, Switzerland, specializing in the research, development, and production of orally dispersible tablets (ODTs) and effervescent tablets. Established in 1983 and formerly known as Aesculapius Pharma SA, the company has gained recognition for its proprietary ODT technology, which enhances the delivery and efficacy of medications. Alpex Pharma operates advanced manufacturing and research facilities covering approximately 7,000 square meters, compliant with Good Manufacturing Practices (GMP) for both pharmaceutical and nutritional products. In addition to its product offerings, the company provides a range of development services, including drug-excipient compatibility studies, analytical method development, and stability studies, positioning itself as a significant player in the fast melt and effervescent tablet markets.

Atlantis Components specializes in the design and manufacturing of titanium abutments for dental implants. The company has developed a software system called the Virtual Abutment Design (VAD) system, which enables technicians to create abutments with unprecedented precision and certainty in the field of implant dentistry. Atlantis Components' designs are informed by extensive dental research and clinical input, allowing dentists to effectively restore implants using crown-and-bridge techniques. The consistent application of the VAD system ensures high-quality outcomes for both single and multiple unit cases, positioning Atlantis Components as a leader in dental implant solutions.

Cedarburg Hauser Pharmaceuticals is an experienced contract development and manufacturing organization (CDMO) for active pharmaceutical ingredients (APIs) and intermediates We offer multiple sites for non-GMP R&D projects, GMP kilo labs for early phase projects and GMP plant capacity for late stage and commercial APIs. We apply our drug development experience and expertise to help our clients successfully advance their drug candidate from early preclinical evaluations through clinical trials and eventually to market.